Isomab Presents Safety Data for Angiogenic Approaches in Coronary Artery Disease

Isomab has published a significant study evaluating the safety profile of angiogenic approaches for treating coronary artery disease (CAD). This marks the first comprehensive systematic review to address long-standing safety concerns that have previously limited progress in the field.

The review of existing data revealed no increased risk of cancer or retinopathy among patients who received angiogenic therapies. These findings align with previous research but provide the first systematic compilation of long-term safety outcomes.

Angiogenic approaches aim to stimulate the formation of new blood vessels, potentially improving blood flow in heart muscle affected by CAD. However, concerns regarding adverse effects, such as an elevated risk of cancer, have hindered wider adoption and research.

Isomab states that the release of this long-term safety data is crucial for advancing clinical research and potentially expanding the use of angiogenic treatments for CAD patients. The company anticipates that these findings will help remove obstacles to the development of new therapeutic options.